Relationship between vascular age and classic cardiovascular risk factors and arterial stiffness

Łoboz-Rudnicka, Maria; Jaroch, Joanna; Bociąga, Zbigniew; Kruszyńska, Ewa; Ciecierzynska, B.; Dziuba, Magdalena; Dudek, Krzysztof; Uchmanowicz, Izabella; Łoboz‐Grudzień, Krystyna

doi:10.5603/cj.2013.0098

Cited by 21 publications

(23 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Providing CDS to patients is congruent with the current emphasis on patient‐centred care and shared decision‐making . From a practical point of view, giving CDS recommendations to patients presents many practical challenges, and evidence is slowly developing on the best way to present information on the risk and benefits of alternative treatment strategies to patients with varying degrees of numeracy and health literacy .…”

Section: Impact Of Cds On Diabetes Care Outcomesmentioning

confidence: 99%

Outpatient diabetes clinical decision support: current status and future directions

et al. 2016

View full text Add to dashboard Cite

Outpatient clinical decision support systems have had an inconsistent impact on key aspects of diabetes care. A principal barrier to success has been low use rates in many settings. Here, we identify key aspects of clinical decision support system design, content and implementation that are related to sustained high use rates and positive impacts on glucose, blood pressure and lipid management. Current diabetes clinical decision support systems may be improved by prioritizing care recommendations, improving communication of treatment-relevant information to patients, using such systems for care coordination and case management and integrating patient-reported information and data from remote devices into clinical decision algorithms and interfaces.

show abstract

Section: Impact Of Cds On Diabetes Care Outcomesmentioning

confidence: 99%

Outpatient diabetes clinical decision support: current status and future directions

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Our study for the first time, reported the changes in vascular age as a result of combination therapy with dulaglutide and SGLT2i. Vascular age reflects the real atherosclerotic damage and is considered as a new variable in cardiovascular risk assessment [11,12]. This study demonstrated significant improvement in vascular age at the follow-up compared with baseline.…”

Section: Discussionmentioning

confidence: 59%

Clinical effectiveness of combination therapy with dulaglutide, SGLT2 inhibitor and metformin with or without insulin in Indian adults with type 2 diabetes: a real-world retrospective study

Bhattacharyya

2020

Clinical Diabetology

View full text Add to dashboard Cite

Background. Antidiabetic agents such as glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium glucose cotransporter-2 inhibitors (SGLT2i) are known to improve glycaemic control with favourable impact on cardiovascular (CV) risk factors. Given the potential benefits, this study evaluated the clinical effectiveness of combination therapy including dulaglutide, SGLT2i and metformin with or without insulin in Indian adults with inadequately controlled T2DM. Material and methods. This retrospective, real-world, single-centre study included 15 adults (mean age [SD, standard deviation]: 49.47 [9.29] years) with inadequately controlled T2DM. The patients received a combination of dulaglutide, SGLT2i and metformin with or without insulin. Changes in fasting blood glucose (FBG), postprandial blood glucose (PPBG), glycosylated haemoglobin (HbA 1c), body weight, BMI, vascular age (VA), systolic blood pressure (SBP) and diastolic blood pressure (DBP) were examined for a follow-up duration of 3 months. Self-reported adverse events were also recorded. Results. At the 3-month follow-up, the combination therapy resulted in significant reduction (P < 0.001) in glycaemic parameters such as FBG, PPBG and HbA 1c with a mean reduction (MR [SD]) of 66.67 (40.05) mg/dL, 83.33 (64.11) mg/dL and 1.78 (1.08) % respectively. A significant reduction (P < 0.001) in body weight and corresponding BMI was demonstrated with an MR (SD) of 6.40 (3.96) kg and 2.67 (1.63) kg/m 2 respectively. Similarly, significant reductions (P < 0.05) were also recorded for SBP (4.40 [4.61] mm Hg) and DBP (2.80 [3.84] mm Hg). The therapy was also associated with significant reduction (P < 0.001) in VA (MR [SD]: 3.93 [2.46] years). The therapy was well tolerated; however, self-reported gastrointestinal symptoms were reported in 5 patients, which subsided within 2 weeks of therapy initiation. Conclusion. Combination therapy with dulaglutide, SGLT2i and metformin with or without insulin resulted in significant improvements in glycaemic parameters, body weight and SBP in Indian adults with inadequately controlled T2DM. Interestingly, there was a significant improvement in vascular age associated with the therapy.

show abstract

“…() have also shown that among traditional CV risk factors type 2 diabetes mellitus was a predictor of the outcome that VA exceeded CA at least 5 years. Furthermore, these authors also found that BMI was an additional marker for advanced VA, but only in female population (Łoboz‐Rudnicka et al ., ). Masson et al .…”

Section: Discussionmentioning

confidence: 93%

“…(), who established that the VA of a person is equal to the age of an individual with the same estimated CV risk, but whose risk factors are within normal range. This point of view introduced the idea: ‘a man is old as his arteries’ which recently has drawn a growing attention in the field of the CV risk assessment (Grundy, ; Rosen et al ., ; Stein, ; Nilsson, ; Łoboz‐Rudnicka et al ., ). Additionally, VA represents the CA adjusted for individual's atherosclerotic burden, thus leading to the fact that there may be a substantial difference between these two types of ages in one person.…”

Section: Introductionmentioning

confidence: 97%

Erectile dysfunction as a predictor of advanced vascular age

et al. 2015

View full text Add to dashboard Cite

SUMMARYVascular age (VA) represents chronological age (CA) adjusted for individual's atherosclerotic burden. The presence of erectile dysfunction (ED) has been considered as a clinical sentinel of premature atherosclerosis. The objective of this study was to explore the predictive value of ED in assessing the discrepancy between VA and CA. In the period from 1 January 2014 to 1 January 2015, all consecutive men referring to the outpatient departments of the Clinics of Urology and Cardiology in Belgrade (Serbia) were considered for enrolment in this cross-sectional study. General exclusion criteria were: age below 18, heart failure, history of myocardial infarction, impaired renal and liver function, acute infection, history of endocrine disease other than type 2 diabetes, pelvic surgery or trauma, and acute coronary syndrome within the last 6 months. According to the presence of ED, hypertension, type 2 diabetes and history of coronary artery disease participants were assigned into five study groups. Hierarchical multiple regression analysis was conducted to identify the predictive value of ED in detection of advanced VA. The mean age of males enrolled in the study was 52.9 AE 7.7 years. The predominance of VA over CA was statistically significantly higher in the group of participants with coexistence of ED and hypertension compared to the group of patients with ED and type 2 diabetes (p = 0.027) and the group of patients with ED (p = 0.014) and control group (p < 0.01). Regression analysis highlighted that ED represented a highly important marker (p < 0.01) of advanced VA, which independently accounted for 6.1% of the variance in the discrepancy between VA and CA. Our study suggests that assessment of ED could be a part of a more comprehensive prediction of patients' advanced VA. Screening among such a highly selected population may help identify those that would most benefit from drug treatments and life style changes.

show abstract

Relationship between vascular age and classic cardiovascular risk factors and arterial stiffness

Abstract: (Cardiol J 2013; 20, 4: 394-401)

Cited by 21 publications

References 30 publications

Outpatient diabetes clinical decision support: current status and future directions

Outpatient diabetes clinical decision support: current status and future directions

Clinical effectiveness of combination therapy with dulaglutide, SGLT2 inhibitor and metformin with or without insulin in Indian adults with type 2 diabetes: a real-world retrospective study

Erectile dysfunction as a predictor of advanced vascular age

Contact Info

Product

Resources

About